Related Experiment Video
Updated: Apr 14, 2026
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
Strategies for decision-making on vaccine use: the French experience
Pierre Loulergue1, Daniel Floret, Odile Launay
1Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417; Assistance Publique Hôpitaux de Paris (AP-HP), Groupe Hospitalier Cochin Broca Hôtel Dieu, CIC Cochin-Pasteur, 27, rue du faubourg Saint Jacques 75014 Paris, France.
Abstract:
France enjoys benefits of a good organization of its healthcare system. National Health Insurance is reimbursing vaccines if they are used according to the national recommendation guidelines. Vaccination is the responsibility of the government, advised by its National Immunization Technical Advisory Group (Comité Technique des vaccinations). But France, like many other countries, faces insufficient involvement from the public in immunization programs and, consequently, numerous outbreaks of vaccine-preventable diseases. The French government launched a 5-year national program for improvement in vaccination policy in 2012 to simplify the guidelines, facilitate access to vaccination, invest in research and evaluate its vaccine policy. The role of the public and healthcare professionals to encourage vaccination is crucial for the future.
